JP6550132B2 - Ｃｄ３８阻害剤及び治療の方法 - Google Patents

Ｃｄ３８阻害剤及び治療の方法 Download PDF

Info

Publication number
JP6550132B2
JP6550132B2 JP2017529357A JP2017529357A JP6550132B2 JP 6550132 B2 JP6550132 B2 JP 6550132B2 JP 2017529357 A JP2017529357 A JP 2017529357A JP 2017529357 A JP2017529357 A JP 2017529357A JP 6550132 B2 JP6550132 B2 JP 6550132B2
Authority
JP
Japan
Prior art keywords
mmol
cyclohexyl
indole
reaction
stirred
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017529357A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018501215A (ja
JP2018501215A5 (OSRAM
Inventor
カディッラ，ロドルフォ
ノーマン デイトン，デヴィッド
ノーマン デイトン，デヴィッド
リチャード ヘンケ，ブラッド
リチャード ヘンケ，ブラッド
プルーグスチャット，フランク
デール ハフナー，カート
デール ハフナー，カート
ブーヘラー，ジェイ．デヴィッド
シュルテ，クリスティー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property No 2 Ltd
Original Assignee
GlaxoSmithKline Intellectual Property No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property No 2 Ltd filed Critical GlaxoSmithKline Intellectual Property No 2 Ltd
Publication of JP2018501215A publication Critical patent/JP2018501215A/ja
Publication of JP2018501215A5 publication Critical patent/JP2018501215A5/ja
Application granted granted Critical
Publication of JP6550132B2 publication Critical patent/JP6550132B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2017529357A 2014-12-03 2015-11-19 Ｃｄ３８阻害剤及び治療の方法 Active JP6550132B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462086844P 2014-12-03 2014-12-03
US62/086,844 2014-12-03
PCT/IB2015/058965 WO2016087975A1 (en) 2014-12-03 2015-11-19 Cd38 inhibitors and methods of treatment

Publications (3)

Publication Number Publication Date
JP2018501215A JP2018501215A (ja) 2018-01-18
JP2018501215A5 JP2018501215A5 (OSRAM) 2018-11-01
JP6550132B2 true JP6550132B2 (ja) 2019-07-24

Family

ID=54708091

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017529357A Active JP6550132B2 (ja) 2014-12-03 2015-11-19 Ｃｄ３８阻害剤及び治療の方法

Country Status (11)

Country Link
US (1) US9840496B2 (OSRAM)
EP (1) EP3227275B1 (OSRAM)
JP (1) JP6550132B2 (OSRAM)
KR (1) KR20170090478A (OSRAM)
CN (1) CN107428733A (OSRAM)
AU (1) AU2015356721B2 (OSRAM)
BR (1) BR112017011642A2 (OSRAM)
CA (1) CA2969178A1 (OSRAM)
ES (1) ES2717260T3 (OSRAM)
RU (1) RU2017121002A (OSRAM)
WO (1) WO2016087975A1 (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7516047B2 (ja) 2016-11-23 2024-07-16 アセチロン ファーマシューティカルズ インコーポレイテッド ヒストン脱アセチル化酵素阻害剤とｃｄ３８阻害剤とを含む医薬組み合わせ物及びその使用方法
AU2020205753B2 (en) 2019-01-11 2025-05-29 Omeros Corporation Methods and compositions for treating cancer
US11535621B2 (en) 2019-07-31 2022-12-27 Ribon Therapeutics, Inc. Heterobicyclic amides as inhibitors of CD38
WO2021087087A1 (en) 2019-10-30 2021-05-06 Mitobridge Inc. N-cyclohexyl-5-(thiazol-5-yl)-1h-indole-7-carboxamide derivatives and related compounds as cd38 inhibitors for increasing nad+ and for the treatment of e.g. muscular disorders
CN115697985B (zh) * 2020-04-07 2025-01-21 米托布里奇公司 Cd38抑制剂
KR20230106605A (ko) * 2020-10-09 2023-07-13 나파 테라퓨틱스 엘티디. Cd38의 헤테로아릴 아미드 억제제
PE20232047A1 (es) 2021-01-29 2023-12-27 Boehringer Ingelheim Int Quinolinas y azaquinolinas como inhibidores de cd38
CN117715897A (zh) * 2021-04-30 2024-03-15 南京艾美斐生物医药科技有限公司 化合物及其作为cd38抑制剂的用途
KR20240047371A (ko) * 2021-07-12 2024-04-12 싸이토키네틱스, 인코포레이티드 Cd38 조절제 및 이의 사용 방법
WO2024254396A1 (en) * 2023-06-07 2024-12-12 Flagship Pioneering Innovations, Vi, Llc Condensed azines as inhibitors of cyclic adp ribose hydrolase
CN119775288B (zh) * 2024-12-31 2025-10-10 浙江工业大学 一种cd38抑制化合物及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002246956B2 (en) * 2001-01-04 2006-11-02 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of ADP-ribosyl transferases, cyclases, and hydrolases, and uses thereof
US7022680B2 (en) * 2002-05-30 2006-04-04 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of ADP-ribosyl transferases, cyclases, and hydrolases
US8283368B2 (en) * 2008-08-29 2012-10-09 The Regents Of The University Of Michigan Selective ligands for the dopamine 3 (D3) receptor and methods of using the same
EP2801573A1 (en) * 2013-05-09 2014-11-12 Sanofi Hydantoine derivatives as CD38 inhibitors

Also Published As

Publication number Publication date
AU2015356721A1 (en) 2017-06-08
CA2969178A1 (en) 2016-06-09
JP2018501215A (ja) 2018-01-18
US20170260164A1 (en) 2017-09-14
AU2015356721B2 (en) 2018-03-15
RU2017121002A (ru) 2019-01-11
BR112017011642A2 (pt) 2018-03-06
WO2016087975A1 (en) 2016-06-09
CN107428733A (zh) 2017-12-01
RU2017121002A3 (OSRAM) 2019-03-15
ES2717260T3 (es) 2019-06-20
KR20170090478A (ko) 2017-08-07
EP3227275B1 (en) 2019-01-02
EP3227275A1 (en) 2017-10-11
US9840496B2 (en) 2017-12-12

Similar Documents

Publication Publication Date Title
JP6550132B2 (ja) Ｃｄ３８阻害剤及び治療の方法
EP3269370B1 (en) Novel condensed pyrimidine compound or salt thereof
EP2603513B1 (en) Heterocyclic compound and use thereof as ampa receptor positive allosteric modulator
CN110028491B (zh) 纤维母细胞生长因子受体抑制剂
EP2630123B1 (en) Substituted 6-amino-nicotinamides as kcnq2/3 modulators
CN105189502B (zh) N‑(4‑(氮杂吲唑‑6‑基)‑苯基)‑磺酰胺及其作为药物的用途
ES2977656T3 (es) Inhibidores de KDM1A para el tratamiento de enfermedades
EP3331863B1 (en) Novel compounds as ror gamma modulators
CN104837825A (zh) 鲁顿酪氨酸激酶抑制剂
AU2015339196A1 (en) Substituted tetrahydropyrans and method of use
CN108314677A (zh) 一种新型的ezh2抑制剂及其用途
EP3287463A1 (en) Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof
UA80184C2 (en) Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
KR20150093229A (ko) Ｐ２ｘ７ 수용체 길항제로서의 인돌 카르복사미드 유도체
WO2018021977A1 (en) Glycine metabolism modulators and uses thereof
Xiao et al. Novel 6-amino-1, 3, 5-triazine derivatives as potent BTK inhibitors: structure-activity relationship (SAR) analysis and preliminary mechanism investigation
EP4043457A1 (en) Aromatic heterocyclic compound having tricyclic structure, and preparation method therefor and application thereof
WO2016121953A1 (ja) 免疫疾患の予防及び／又は治療剤
Mésangeau et al. Preparation and pharmacological evaluation of a novel series of 2-(phenylthio) benzo [b] thiophenes as selective MT2 receptor ligands
EP3426638B1 (en) Inhibitors of indoleamine 2,3-dioxygenase
CN108341816A (zh) 一种选择性抑制激酶化合物
CA3163568A1 (en) Isoquinoline derivatives for use in treating glut1 deficiency syndrome
JP2022550886A (ja) 新規なピリジン－２（１ｈ）オン誘導体、その調製、及び疼痛を処置するためのその使用
CN118359542A (zh) 一种多取代的吡唑类化合物及其制备方法和用途
HK40056552A (en) Prophylactic and/or therapeutic agent for immune diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180918

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180918

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190613

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190625

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190628

R150 Certificate of patent or registration of utility model

Ref document number: 6550132

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350